East is the industry standard platform for clinical trial design, simulation, and monitoring, improving scientific productivity during the critical planning stages of clinical development. In this blog, our Hrishikesh Kulkarni takes us on a tour of his life as a Cytel software trainer and answers some frequently asked questions about how East training sessions work in practice.
Photo by Dose Media on Unsplash
By Charles Liu, Senior Product Manager, Cytel
Several years ago, I was one of few Luddites in my social circle still using a “dumb” phone. Other than calls, and (text only!) messaging, it had no other functionality. Once I made the switch, a whole new magical world unveiled itself. With the tap of a button, I could read my email, listen to a podcast, find a...
Topics: Trial Design Software, EAST 6.4, Sample Size
The Cytel YouTube Channel hosts a wealth of video presentations from Cytel experts as well as external industry and academic speakers about various aspects of clinical trial designs and their implementation. In this blog, we've gathered 6 popular resources from the channel on topics from quantitative decision-making through to overcoming challenges in management of oncology trials. Read on...
Topics: biostatistics, Adaptive Clinical Trials, adaptive designs, Multi-Arm Multi-Stage Studies, Multi-Arm Studies, EAST 6.4, East PREDICT, pharmacometrics, model-informed-drug-development, Cytel Videos
In 2011, Cytel organized its first East User Group Meeting (EUGM) in Paris. Since then, we have held an EUGM almost every year, alternating between locations in Europe and North America. These meetings have been a great success, giving opportunities for customers and industry colleagues to meet each other as well as with key opinion leaders, whilst learning more about our East software and...
Topics: EAST 6.4, Adaptive Clinical Trials, adaptive trials, Statistical Innovations in Clinical Development, Clinical Development Strategy, Cytel Strategic Consulting
Since 2011 we have been celebrating Cytel's birthdays by holding an East Annual Symposium and User Group Meeting ( EUGM), alternating locations between Europe and the United States. Our keynote speakers have featured some of the industry's most eminent biostatistics thought leaders including Stuart Pocock, Dave DeMets, Chris Jennison, Sue Todd, and Franz Koenig. Each annual event has been a...
Topics: biostatistics, adaptive designs, Adaptive Clinical Trials, East, EAST 6.4, Dose-Escalation, Multi-Arm Multi-Stage Studies
Case studies:Learning from less-well understood adaptive designs
Posted by Cytel
Sep 29, 2016 9:28:14 AM
A paper "Best practices case studies for 'less well-understood' Adaptive designs", has been published by the DIA Scientific Working Group on Adaptive Designs as a twin document to the previously discussed "Challenges and Opportunities of 'Less Well Understood' Adaptive Designs". This publication furthers understanding by reviewing 10 important case studies and sharing details on their design...
Topics: Clinical Development Strategy, adaptive designs, adaptive trials, Adaptive Clinical Trials, adaptive sample size re-estimation, Seamless designs, Rare Disease, Multi-Arm Multi-Stage Studies, Multi-Arm Studies, EAST 6.4
Challenge:
Our client, an emerging biotechnology company, was preparing for the next stage of development for their novel compound in a rare disease. They had two major concerns which they wanted the clinical trial design to address- an anticipated difficulty in recruiting subjects to the trial, and the cost and time investment associated with running separate phase 2 and phase 3 trials. ...
Topics: biostatistics, adaptive trials, EAST 6.4, Seamless designs, phase 2, Phase 3, Clinical Research Services, Cytel Strategic Consulting
Topics: biostatistics, adaptive trials, Dose-Escalation, EAST 6.4, East ESCALATE, BLRM, CRM, Oncology, Early Phase Trials, Eearly Development
Traditional rule-based approaches to dose escalation such as 3+3 are widely used in early clinical development. They can be appealing due to the simplicity of execution. However, estimates produced may be highly variable and the targeting of true Maximum Tolerated Dose may be poor. Bayesian dose escalation approaches in early phase trials can offer an effective alternative to determining the...
Topics: biostatistics, adaptive trials, Dose-Escalation, EAST 6.4, East ESCALATE, BLRM, CRM
Webinar Replay: Single and Double Agent Dose Escalation Designs
Posted by Cytel
Jul 21, 2016 6:30:00 AM
Did you miss our webinar on Single and Dual Agent Dose escalation designs earlier in the year? In this blog we have made the replay available for your review, and also take the opportunity to recap key reasons why you should consider a model based design for your dose escalation study.
Topics: Oncology, Dose-Escalation, Bayesian Methods, EAST 6.4
At a recent PhUSE SDE, Cytel’s Chitra Tirodkar presented how East PROC MCPMod could be used to help solve the problem of uncertain true dose-response relationship in a bronchodilator study. In this blog we summarize some of the issues, and make Chitra's slides available for download.
Topics: Dose-Finding, Dose Selection, MCP-Mod, Statistical Programming, SAS, East, EAST 6.4
Predicting the course of a clinical trial is something which people will always want to do-whether for statistical reasons, planning reasons or business reasons. In this blog we look at examples of where prediction goes off course, and how we can resolve these issues. We also share valuable video and slidedeck resources from our VP Consulting and Software, Yannis Jemiai.
Topics: East, East PREDICT, Interim Analyses, Cytel Videos, Cytel Events, clinical development, EAST 6.4, adaptive designs, adaptive trials, DMC
Last week, we were delighted to announce the release of East 6.4 bringing further cutting –edge approaches to the East user community. East is the industry standard platform for clinical trial design, simulation, and monitoring, improving scientific productivity during the critical planning stages of clinical development. In this blog we catch up with Yannis Jemiai, VP of Cytel to gain some...
Topics: East, Bayesian Methods, East PREDICT, Prediction, Software Simulations, Multi-Arm Studies, Multi-Arm Multi-Stage Studies, biostatistics, EAST 6.4, adaptive trials
There has been increasing interest in multi-arm multi-stage trials with treatment selection and sample size re-estimation at interim analysis. The East 6.4 release incorporates new Multi-Arm Multi-Stage (MAMS) module to support statisticians designing these studies. In this blog, we take a high level look at some of the features and advantages of this approach.
Topics: East, Adaptive Clinical Trials, Multi-Arm Studies, Multi-Arm Multi-Stage Studies, EAST 6.4
5 Reasons to Invest in Bayesian Dose-Escalation Methods
Posted by Esha Senchaudhuri
May 8, 2014 7:54:00 AM
( Editor's note: This post has been refreshed in December 2016)
Model based algorithms for Phase I dose-escalation have been in existence for nearly thirty years. Despite guarantees of increased statistical power and greater accuracy, there remains a clear preference for rule based algorithms amongst clinicians. The explanation for this is as old as the models themselves.
Topics: Oncology, Dose-Escalation, Bayesian Methods, EAST 6.4, East ESCALATE
The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics. Sign up for updates direct to your inbox. You can unsubscribe at any time.
Posts by Topic
- biostatistics (96)
- Adaptive Clinical Trials (82)
- Statistical Programming (56)
- Clinical Research Services (51)
- Clinical Development Strategy (47)
- adaptive designs (46)
- Oncology (40)
- Clinical Data (38)
- adaptive trials (35)
- Statistical Analysis (32)
- Data Management (31)
- Bayesian Methods (30)
- clinical trials (27)
- Cytel Strategic Consulting (25)
- Trial Design (23)
- CDISC (22)
- clinical research (21)
- Cytel Consulting (20)
- Early Phase Trials (20)
- Phase 3 (20)
- East (19)
- Interim Analyses (19)
- pharmacometrics (19)
- Phase 1 (18)
- phase 2 (18)
- Regulation (17)
- data manager (17)
- SDTM (16)
- careers (16)
- clinical development (16)
- data science (16)
- EAST 6.4 (15)
- EDC (15)
- SAS (15)
- patient enrollment (15)
- Cyrus Mehta (14)
- Dose-Escalation (14)
- Simulations (13)
- CRO (12)
- Dose-Finding (12)
- FDA (12)
- Program and Portfolio Optimization (12)
- Promising Zone (12)
- Statistical Innovations in Clinical Development (12)
- database build (12)
- pharmacology (12)
- Cardiovascular (11)
- adaptive sample size re-estimation (11)
- Biometrics (10)
- Entrepreneurship (10)
- Recruitment (10)
- ADaM (9)
- Precision Medicine (9)
- big data (9)
- clinical data management (9)
- outsourcing (9)
- Access to Slides PDF (8)
- Bayesian (8)
- CDM (8)
- East 6.3 (8)
- R programming (8)
- Trial Quality (8)
- go-no-go (8)
- sample size re-estimation (8)
- Case Study (7)
- Multi-Arm Multi-Stage Studies (7)
- Multi-Arm Studies (7)
- Phase I (7)
- Software Simulations (7)
- enforesys (7)
- model-informed-drug-development (7)
- quantitative decision-making (7)
- BLRM (6)
- DMC (6)
- East ESCALATE (6)
- East PREDICT (6)
- Enrichment (6)
- Nitin Patel (6)
- R language (6)
- Training and Education (6)
- feasibility studies (6)
- Biomarkers (5)
- Cytel Videos (5)
- MCP-Mod (5)
- Marvin Zelen (5)
- R (5)
- Sample Size (5)
- real world evidence (5)
- ACES (4)
- Access to Paper PDF (4)
- CDASH (4)
- CRM (4)
- Exact Tests (4)
- Prediction (4)
- Predictive Enrichment (4)
- Rare Disease (4)
- Rstats (4)
- Safety (4)
- Seamless designs (4)
- Small Sample Sparse Data (4)
- StatXact (4)
- Trial Design Software (4)
- Trial Monitoring (4)
- forecasting (4)
- randomization (4)
- Cytel Events (3)
- Dose Selection (3)
- Group Sequential (3)
- JSM (3)
- PK/PD (3)
- PSI Conference (3)
- PhUSE (3)
- Proof-of-Concept (3)
- R&D (3)
- Simulation & Biomarkers (3)
- Statistical Puzzles (3)
- White Paper (3)
- basket trials (3)
- custom software (3)
- exact statistics (3)
- genetic algorithm (3)
- machine learning (3)
- meta-analysis (3)
- optimization (3)
- p value (3)
- type 1 error (3)
- Adaptive Finance (2)
- Blind and Unblind Trials (2)
- Compass (2)
- Computing (2)
- EMA (2)
- Education (2)
- Efficacy (2)
- Lingyun Liu (2)
- Medical Devices (2)
- Monte Carlo (2)
- Movers & Shapers (2)
- NONMEM (2)
- PMDA (2)
- Pediatric (2)
- biomedical signals (2)
- estimands (2)
- patientricity (2)
- personalized medicine (2)
- pharmacovigilance (2)
- psychiatry and neuroscience (2)
- signal detection (2)
- trial planning (2)
- Adaptive Licensing (1)
- Antibiotic resistance (1)
- Biosimilars (1)
- Composite Endpoints (1)
- Cytel CliPLab (1)
- Cytel Congratulates (1)
- East Recruit (1)
- Eearly Development (1)
- Evidence Based Medicine (1)
- Exact Inference (1)
- Exact tests for categorical data (1)
- FMCG (1)
- Fourier (1)
- HTA (1)
- ISE (1)
- ISS (1)
- Infectious Diseases (1)
- NICE (1)
- PIPE (1)
- PSI (1)
- Predicted Interval Plots (1)
- RFP (1)
- Richard Branson (1)
- Risk Based Monitoring (1)
- Sam Hsaio (1)
- Scope conference (1)
- Statistics Article full PDF (1)
- Translational Medicine (1)
- Translational Statistics (1)
- Webinar Slides (1)
- What are... (1)
- benefit risk assessment (1)
- feature selection (1)
- health economics (1)
- immunotherapy (1)
- infographic (1)
- medical ethics (1)
- medical writing (1)
- non parametric analysis (1)
- pattern recognition (1)
- permutations (1)
- population enrichment (1)
- signal processing (1)
- statistical communication (1)
- subgroup analysis (1)
- t-tests (1)
- time to event trials (1)
- time-to-even trials (1)
- treatment switch (1)
- webinar (1)